AR and prostate carcinoma: In further confirmation of this hypothesis, the same experiment was repeated with an additional pretreatment step using the chemotherapeutic agent bicalutamide, an AR competitive inhibitor approved for prostate cancer therapy under the trade name Casodex [13].